Ado-trastuzumab emtansine (T-DM1) in HER2+advanced breast cancer patients: does pretreatment with pertuzumab matter?

被引：23

作者：

Fabi, Alessandra ^{[1
]}

Giannarelli, Diana ^{[2
]}

Moscetti, Luca ^{[3
]}

Santini, Daniele ^{[4
]}

Zambelli, Alberto ^{[5
]}

De laurentiis, Michelino ^{[6
]}

Caruso, Michele ^{[7
]}

Generali, Daniele ^{[8
]}

Valle, Enrichetta ^{[9
]}

Leonardi, Vita ^{[10
]}

Cannita, Katia ^{[11
]}

Arpino, Grazia ^{[12
]}

Filippelli, Gianfranco ^{[13
]}

Ferretti, Gianluigi ^{[1
]}

Giampaglia, Marianna ^{[14
]}

Montemurro, Filippo ^{[15
]}

Nistico, Cecilia ^{[1
]}

Gasparro, Simona ^{[1
]}

Cognetti, Francesco ^{[1
]}

机构：

[1] Ist Nazl Tumori Regina Elena, Oncol Med 1, I-00144 Rome, Italy

[2] Ist Nazl Tumori Regina Elena, Unita Biostat, I-00144 Rome, Italy

[3] Osped Modena, Oncol Med, I-41125 Modena, Italy

[4] Campus Biomed Univ, Oncol Med, I-00128 Rome, Italy

[5] Osped Papa Giovanni XXIII, Oncol Med, I-24127 Bergamo, Italy

[6] Ist Pascale, Breast Unit, I-80131 Naples, Italy

[7] Humanitas Ctr Catanese Oncol, I-95126 Catania, Italy

[8] Univ Trieste, Dipartimento Univ Clin Sci Med Chirurg & Salute, I-34127 Trieste, Italy

[9] Osped Businco, Oncol Med, I-09121 Cagliari, Italy

[10] ARNAS Civ, Oncol Med, I-90127 Palermo, Italy

[11] Osped Aquila, Oncol Med, I-67100 Laquila, Italy

[12] Univ Federico II, Oncol Med, I-80138 Naples, Italy

[13] ASP Cosenza, Oncol PO Paola, Cosenza, Italy

[14] Osped San Carlo Borromeo Milano, Oncol Med, I-85100 Potenza, Italy

[15] Fdn Piemonte Oncol, Ist Tumori Candiolo, I-10060 Turin, Italy

来源：

FUTURE ONCOLOGY | 2017年 / 13卷 / 30期

关键词：

HER2-positive tumors; HER2; second-line; metastatic breast cancer; pertuzumab; T-DM1; MONOCLONAL-ANTIBODY; PLUS DOCETAXEL; CHEMOTHERAPY; EFFICACY; SAFETY;

D O I：

10.2217/fon-2017-0336

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Aim: We evaluated the outcomes of patients treated with ado-trastuzumab emantasine (T-DM1) after first-line pertuzumab/trastuzumab, compared with those receiving a trastuzumab-only-based regimen. Patients & methods: Patients who received second-line T-DM1 after pertuzumab/trastuzumab (n = 34) were compared with those who received only trastuzumab (n = 73). Results: Overall response rate was 33.3% in patients with prior pertuzumab and 57.1% in the remaining subjects. Disease control rate was 47 and 43%, respectively, and the clinical benefit rate was 43.3 and 71.1%, respectively. Median progressionfree survival was 5.0 and 11.0 months, respectively (hazard ratio: 2.02; 95% CI: 1.14-3.58; p = 0.01). Conclusion: Patients treated with T-DM1 who previously received pertuzumab present poorer clinical outcomes compared with those receiving a trastuzumab-only-based regimen in the first-line setting.

引用

页码：2791 / 2797

页数：7

共 12 条

[1] Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer [J].

Baselga, Jose ;

Cortes, Javier ;

Kim, Sung-Bae ;

Im, Seock-Ah ;

Hegg, Roberto ;

Im, Young-Hyuck ;

Roman, Laslo ;

Pedrini, Jose Luiz ;

Pienkowski, Tadeusz ;

Knott, Adam ;

Clark, Emma ;

Benyunes, Mark C. ;

Ross, Graham ;

Swain, Sandra M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (02) :109-119

[2] Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease [J].

Cobleigh, MA ;

Vogel, CL ;

Tripathy, D ;

Robert, NJ ;

Scholl, S ;

Fehrenbacher, L ;

Wolter, JM ;

Paton, V ;

Shak, S ;

Lieberman, G ;

Slamon, DJ .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (09) :2639-2648

[3] T-DM1 Activity in Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancers That Received Prior Therapy With Trastuzumab and Pertuzumab [J].

Dzimitrowicz, Hannah ;

Berger, Michael ;

Vargo, Craig ;

Hood, Annette ;

Abdelghany, Osama ;

Raghavendra, Akshara Singareeka ;

Tripathy, Debu ;

Valero, Vicente ;

Hatzis, Christos ;

Pusztai, Lajos ;

Murthy, Rashmi .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (29) :3511-+

[4] Efficacy and safety of T-DM1 in the 'common-practice' of HER2+advanced breast cancer setting: a multicenter study [J].

Fabi, Alessandra ;

De laurentiis, Michelino ;

Caruso, Michele ;

Valle, Enrichetta ;

Moscetti, Luca ;

Santini, Daniele ;

Cannita, Katia ;

Carbognin, Luisa ;

Ciccarese, Mariangela ;

Rossello, Rosalba ;

Arpino, Grazia ;

Leonardi, Vita ;

Montemurro, Filippo ;

La Verde, Nicla ;

Generali, Daniele ;

Zambelli, Alberto ;

Scandurra, Giuseppa ;

Russillo, Michelangelo ;

Paris, Ida ;

D'Ottavio, Anna Maria ;

Filippelli, Gianfranco ;

Giampaglia, Marianna ;

Stani, Simonetta ;

Fabbri, Agnese ;

Alesini, Daniele ;

Cianniello, Daniela ;

Giannarelli, Diana ;

Cognetti, Francesco .

ONCOTARGET, 2017, 8 (38) :64481-64489

[5] Phase II Randomized Study of Trastuzumab Emtansine Versus Trastuzumab Plus Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer [J].

Hurvitz, Sara A. ;

Dirix, Luc ;

Kocsis, Judit ;

Bianchi, Giulia V. ;

Lu, Janice ;

Vinholes, Jeferson ;

Guardino, Ellie ;

Song, Chunyan ;

Tong, Barbara ;

Ng, Vivian ;

Chu, Yu-Waye ;

Perez, Edith A. .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (09) :1157-1163

[6] Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial [J].

Krop, Ian E. ;

Kim, Sung-Bae ;

Gonzalez-Martin, Antonio ;

LoRusso, Patricia M. ;

Ferrero, Jean-Marc ;

Smitt, Melanie ;

Yu, Ron ;

Leung, Abraham C. F. ;

Wildiers, Hans .

LANCET ONCOLOGY, 2014, 15 (07) :689-699

[7]

Luen SJ, 2017, LANCET ONCOL, V18, P52, DOI [10.1016/s1470-2045(16)30631-3, 10.1016/S1470-2045(16)30631-3]

[8] Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2-Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study [J].

Perez, Edith A. ;

Barrios, Carlos ;

Eiermann, Wolfgang ;

Toi, Masakazu ;

Im, Young-Hyuck ;

Conte, Pierfranco ;

Martin, Miguel ;

Pienkowski, Tadeusz ;

Pivot, Xavier ;

Burris, Howard, III ;

Petersen, Jennifer A. ;

Stanzel, Sven ;

Strasak, Alexander ;

Patre, Monika ;

Ellis, Paul .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (02) :141-+

[9] Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. [J].

Slamon, DJ ;

Leyland-Jones, B ;

Shak, S ;

Fuchs, H ;

Paton, V ;

Bajamonde, A ;

Fleming, T ;

Eiermann, W ;

Wolter, J ;

Pegram, M ;

Baselga, J ;

Norton, L .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (11) :783-792

[10] Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer [J].

Swain, Sandra M. ;

Baselga, Jose ;

Kim, Sung-Bae ;

Ro, Jungsil ;

Semiglazov, Vladimir ;

Campone, Mario ;

Ciruelos, Eva ;

Ferrero, Jean-Marc ;

Schneeweiss, Andreas ;

Heeson, Sarah ;

Clark, Emma ;

Ross, Graham ;

Benyunes, Mark C. ;

Cortes, Javier .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (08) :724-734

← 1 2 →